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Background: One fourth of the adult population in Europe suffer from respiratory allergy. Subcutaneous-allergen-
specific-immunotherapy (SCIT) has long-term disease modifying effect on disease specific Health-Related Quality of
Life (HRQoL). The purpose of this study was to assess the effect of SCIT on alternative disease outcomes in patients
with grass-pollen and/or house dust mite induced allergic rhino-conjunctivitis and/or an asthma diagnosis. Focus
was on expressing outcomes in terms of generic quality of life (Quality-Adjusted-Life-Years (QALY)) and reductions
in sick days.
Methods: The study was a multi-centre study with prospective follow-up. 248 patients were initiated on SCIT. The
disease specific Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ) and two generic (HRQoL) instruments 15D
and EQ-5D were used at baseline and at follow-up. The outcome measures included change in; disease severity,
RQLQ-scores, number of days with symptoms- and number of sick days per year and finally changes in generic
HRQoL and thus, QALY. Disease severity was assessed by specialist doctors; severity of rhino-conjunctivitis was
classified according to the Allergic Rhinitis and its Impact on Asthma (ARIA) and asthma severity according to the
Global Initiative for Asthma (GINA guideline). The remaining outcome measures were assessed by the patients in
questionnaires at baseline and at follow-up. An intension to treat approach was applied. For missing items
imputation of sample mean base-line values or follow-up values were used after specified criteria. The effect of SCIT
on rhino-conjunctivitis and/or asthma diagnoses was analysed at follow-up using three logistic regression models.
Results: The disease severity showed significantly improved disease control. Mean RQLQ-score was reduced from
3.02 at baseline to 2.00 at follow-up. Average annual days with symptoms were reduced from 189 to 145 days
whilst annual sick days were reduced from 3.7 to 1.2 days. The 15D-score increased from 0.83 to 0.86 and the
EQ-5D-score from 0.70 to 0.77, which indicated an annual gain per patient of 0.03-0.06 QALY.
Conclusions: Allergic patients suffering from rhino-conjunctivitis alone or rhino-conjunctivitis and asthma
experience significantly increased HRQoL and they gain 0.03-0.06 QALY, when treated with SCIT for one year.
Trial registration: The study was registered at ClinicalTrials.gov with the identifier: NCT01486498.
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Respiratory allergic disorders constitute a considerable
public health problem in Europe [1,2]. Grass pollen
and house dust mites (HDM) are the most common
allergens causing allergic rhino-conjunctivitis (RC)
and/or asthma. Approximately one fourth of the adult
population in Europe suffer from respiratory allergy
and the prevalence of grass pollen allergy is on average
18% [3,4].
Interventions against respiratory allergy include symp-
tomatic treatment, allergen avoidance and allergen spe-
cific immunotherapy. Subcutaneous allergen specific
immunotherapy (SCIT) involves injections with increas-
ing doses of specific allergen vaccine until a mainten-
ance dose is reached, and at regular intervals for 3 years
thereafter [5].
Controlled studies have documented that during the
pollen season SCIT significantly increases disease specific
health related quality of life (HRQoL), reduces symptoms
and use of medication [6], and may reduce the risk of de-
veloping new allergies and asthma [7,8], however, to our
knowledge no studies have investigated the impact of
SCIT treatment on generic HRQoL, disease severity classi-
fications and sick days per year in a real life setting.
Relevance of number of sick days and days with al-
lergy symptoms are documented by several studies.
One US study documented an annual at-work produc-
tivity loss from allergic RC of $ 2.4 - 4.6 billion, with
losses aggravated by the use of sedating antihistamines
[9]. Another US study showed that 55% of employees
reported RC symptoms for an average of 52.5 days,
were absent 3.6 days per year due to the condition, and
were unproductive 2.3 hours per workday when experi-
encing symptoms, resulting in a productivity loss of $
593 per year per employee with allergic RC [10]. A Da-
nish study found that RC patients were absent 2.7 days
per year [11], and a Swedish study estimated mean RC
absenteeism to 2.3 days per year [12].
Moreover, it is widely acknowledged that the personal
burden of illness, as perceived by the allergic RC and/
or asthma patient, cannot be fully assessed by trad-
itional measures, such as clinical symptoms, which cor-
relates only moderately with patients’ perceptions and
functional capabilities on a daily basis [13,14]. For that
reason it is essential to include the patients self-rated
HRQoL in evaluations of SCIT interventions.
Recently three self-rated HRQoL instruments were
used in parallel to study the baseline HRQoL among 248
Danish allergic RC and/or asthma patients before start
of SCIT with grass pollen and/or HDM. The three in-
struments were the disease specific RC Quality of Life
Questionnaire (RQLQ) [15] and two generic instruments
EQ-5D and 15D [16,17]. Especially the 15D instrument
was able to distinguish HRQoL on a day with allergenexposure from a day without [18-20]. The present study
is a follow-up study of this baseline HRQoL study [18].
Economic evaluations frequently measure health
outcomes in quality-adjusted life years (QALYs), which
is a composite measure combining health-related
quality of life (HRQoL) with life expectancy. Typically,
generic HRQoL measures are used which provide an
index score for various health states (a numerical
score that reflects the preferences of the general popu-
lation regarding a health state compared to other
health states). The EQ-5D instrument and the 15D in-
strument are examples of such generic index-based
HRQoL measures.
This study which focuses on both patient related out-
comes and specialist doctors’ evaluations in a real life
setting made effort in order to capture all possible con-
sequences of SCIT by focussing on multiple dimensions
of the public health disease burden. The aim is to ana-
lyse and report any effect of SCIT on the following five
main outcomes and to calculate a QALY estimate.
1. Disease severity according to international guidelines
2. Disease specific HRQoL (RQLQ)
3. Generic HRQoL (EQ-5D and 15D)
4. Number of days with allergy symptoms per year and
5. Number of sick days per year in patients suffering
from RC, with or without asthma, due to grass
pollen and/or HDM allergy.
Methods
The study was a multi-centre study with prospective
follow-up. Patients (>16 years) were recruited consecu-
tively from 13 clinics specialised in specific allergy
management. The patients were referred to specialist
centres by general practitioners for treatment of grass
pollen and/or HDM allergy with an indication to ini-
tiate SCIT during autumn 2005- spring 2006 and again
during autumn 2006- spring 2007, inclusion was not
performed during the grass pollen season (GPS). A
diagnosis of an allergy to grass pollen and HDM was
established with a combination of a relevant clinical
history and symptomatology and a skin prick test >
3 mm in diameter and/or presence of allergen specific
IgE in serum i.e. spec. IgE > 0.35 kU/L.
Follow-up data was collected on average 14.8 months
(SD: 3.2), median: 14.1 month (range: 8.5-25.9) after the
first injection date: the first injection date corresponds to
our baseline measurements. A total of 248 patients were
included (127 with RC only, 121 with RC and asthma).
The patients’ mean age was 33.4 (SD 10.8). Treatment was
performed using Alutard SQ® Phleum pratense and/or
Alutard SQ® Dermatophagoides pteronyssinus. The main-
tenance dose was 100.000 SQ units every 6 weeks (ALK-
Abello, Horsholm, Denmark).
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ible in the SCIT program, and had available follow-up
data. The reason for dropout was that the patients did
not return the follow-up questionnaires, although they
were reminded two times.
Doctor’s questionnaire at baseline and at follow-up
(objective/clinical measures)
The specialist doctors provided information about the pa-
tients’ general health, disease duration, lung function, and
treatment modality and they diagnosed the patients’ dis-
ease severity. RC severity was classified according to the
Allergic Rhinitis and its Impact on Asthma (ARIA), as
intermittent or persistent and as mild or moderate-severe
[21], and asthma severity according to the Global Initiative
for Asthma (GINA guideline) as intermittent, mild persist-
ent, moderate persistent or severe persistent [22].
Patients’ questionnaire at baseline and at follow-up
The patients’ questionnaires were filled out by the pa-
tients themselves in the specialist doctors’ waiting rooms
and collected immediately before SCIT was initiated
(baseline), and again after one year (follow-up). The pa-
tient questionnaire included the RQLQ, EQ-5D and 15D
instruments, questions concerning number of sick days
and days with allergy symptoms in the last year as well
as socio-demographic items. The reason for using these
two generic instruments was to investigate their ability
to measure HRQoL in AR and allergic asthma patients,
and to increase the robustness of the results by using
two different instruments.
RQLQ has 28 questions in seven domains. The overall
RQLQ score is the mean of all 28 responses and the do-
main score is the average score within each domain. Each
item has seven levels on an ordinal scale with zero denot-
ing “Not troubled” and six “Extremely troubled”. Patients
were asked to fill in the RQLQ items for a typical day with
allergic symptoms, instead of last week as prescribed by
the standard RQLQ, thereby avoiding distributing ques-
tionnaires both in and out of the pollen season.
The 15D questionnaire is a generic self-administrated
multi-attribute HRQoL measure assessing health status
across 15 dimensions [17]: mobility, vision, hearing,
breathing, sleeping, eating, speech, eliminations, usual
activities, mental function, discomfort and symptoms, de-
pression, distress, vitality, and sexual activity. Each dimen-
sion has five levels, ranging from level one indicating no
problems in the dimension to level five signifying extreme
problems. The 15 dimensions with the five levels consti-
tute a health state descriptive system which was used to
calculate a single index score, the 15D-score. The 15D-
score represents the value of the individual respondents
overall HRQoL on a scale from zero (equivalent of being
dead) to one (equivalent to full health, i.e. no problems onany dimension). The valuation was based on a set of pref-
erence weights, elicited from general Danish population
[23]. A difference of 0.03 or more in the 15D score is con-
sidered clinically important in the sense that it has been
found that a person can feel such a difference [24].
The EQ-5D instrument is an alternative health state
descriptive system which consists of five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each item has three levels: no prob-
lems, some problems, or extreme problems. Thus, this
system represents 243 possible health states. We used
the Danish population’s preference weights for these
health states to convert the observed health states to a
single index score, EQ-5D score, where 1.0 is full health
and 0 is dead, and negative scores are considered by the
general population as being ‘worse than death’ [23,25].
For the 15D and the EQ-5D items, respondents were
asked, both at baseline and at follow-up, to report their
general health state on a typical day with allergy symp-
toms as well as on a typical day without allergy symp-
toms, instead of their health status today as prescribed
by the standard questionnaires. This approach was
deemed more appropriate in this case, where symptoms
vary from day to day and in and out of season. To sup-
plement this information, respondents were asked to re-
port the number of days in the year that they experience
inconvenience from these allergy symptoms, as well as
the number of sick days absenteeism (days absent from
work) due to allergy symptoms. The latter information
was used to estimate productivity loss.
A simple equation of the quality-adjusted life-years
(QALY) difference per SCIT treated patient per year was
fitted both for the 15D and the EQ-5D scores:
ΔQALY ¼ a−bð Þ n
365
þ c−bð Þ m
365
where a and b is the HRQol score when experiencing al-
lergy symptoms after and before SCIT respectively, and
c is the HRQol score on a day without allergy symptoms,
n is the number of days with allergy symptoms after
SCIT, and m is the number of days of allergy symptoms
avoided after SCIT.
In the intention to treat (ITT) approach the baseline
scores were used also (imputed) as follow-up scores for
the drop-outs considering the following variables: RC and
A diagnoses, HRQoL-scores (EQ-5D, 15D and RQLQ),
number of sick days, and days with inconvenience, be-
cause of allergy symptoms.
Pollen counts
As the severity of symptoms of allergic patients is
dependent on allergen exposure, any clinical improve-
ment caused by intervention should be evaluated by tak-
ing allergen exposure into account [26]. In Denmark
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collected at two stations, Copenhagen and Viborg. In
this study the cumulated pollen count measured in
grains/m3 during peak season was calculated as the
highest sum of 15 consecutive days based on a daily
pollen count representing an average between the two
pollen stations.
Statistical analyses
Statistical analyses were performed using STATA
11.0. Continuous variables were described as mean
±1 standard deviation (SD) and categorical variables
were described as frequencies. Chi-squared tests
were used to test differences on categorical variables.
Normal distributed data were analysed using
matched paired t-test. Where data was not normally
distributed Wilcoxon-signed-rank-test was used for
ordinal paired variables [27].
For missing items on the HRQoL-scores imput-
ation of sample mean base-line values or follow-up
values were used, respectively, if no more than one
item was missing in the EQ-5D questionnaire, no
more than four items in the 15D questionnaire and
no more than seven items in the RQLQ question-
naire. If these criteria were not met the observation
was not included in the statistical analyses.
The effect of SCIT on RC and/or asthma diagnoses
was analysed at follow-up using three logistic regression
models (the difference between the three models was






9 years or less school education
Other education or unknown
Vocational education and training
Short or medium high education
University degree
Body mass Index
Underweight (less than 18.5 kg)
Normal weight (18.5 to < =25 kg)
Overweight (25 to < = 30 kg)
Fat (more than 30 kg)
Household income in € in the year 2006 per person in the household
Never smoker
Distance to vaccination place in km
*Significant difference (p < 0.05) from baseline to follow-up. aPearsons x2, bt-test.model included the RQLQ-scores, one model the EQ-
5D-scores and one model the 15D-scores, respectively).
Observations, where all dichotomous variables were
zero, represented the reference patient for the analysis.
For example, the reference patient in the regression
model was a male, treated with grass pollen vaccine, and
classified as “no or mild hay fever” without asthma. In
all analyses a 5% significance level was used.Ethical considerations
The study was approved by the Danish Data Agency
(2005-41-5534). The scientific ethics committee did not
find that the project needed permission from their com-
mittee. All patients gave their informed consent prior to
inclusion in the study.
The study was registered at ClinicalTrials.gov with the
identifier: NCT01486498. Details of the registration can
be found at the website of the International Committee
of Medical Journal Editors (ICMJE), www.icmje.org.Results
The sample
Table 1 presents the socio-economic profile of the vacci-
nated patients at baseline (N = 248) and at follow-up
(N = 204). The table allows for a comparison of persons
included at baseline and persons who were successfully
followed up and the p-values refer to the drop-out
analyses.[] number of observations, P-value refers to the
Baseline [248] (100%) Follow-up [204] (82.3%) P-value
126 (50.8) 110 (53.9) *0.035a
31 (12.5) 20 (9.8) 0. 080a
13 (5.2) 10 (4.9)
30 (12.1) 25 (12.3)
90 (36.3) 77 (37.8)
84 (33.9) 72 (35.3)
24.78 (5.21) [246] 25.00 (5.52) [203] 0.143b
6 (2.4) 5 (2.5) 0.533a
150 (60.5) 120 (58.8)
67 (27.0) 57 (27.9)
25 (10.1) 22 (10.8)
31,372 (18,061) [214] 32,091 (17,918) [180] 0.181b
163 (66.0) [247] 134 (66.0) [203] 0.990a
12.9 (18.0) 12.1 (16.6) 0.154b
Figure 1 Cumulated grass pollen counts for the three years of the study period and a corresponding flow of the 183 grass pollen
allergic patients inclusion- and follow-up year.
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line sample, but an overweight of patients with
higher level of education. More women were lost at
follow-up, and there was a tendency for those with
lower levels of education to drop out.
At baseline, 169 patients started SCIT with grass
pollen immunotherapy only, 25 started SCIT with HDM
immunotherapy only, and 54 started treatment with
both grass pollen and HDM immunotherapy. 127 of the
patients were suffering from RC only and 121 were suf-
fering from RC + asthma. At baseline 15 of the patients
were classified as intermittent RC and 233 as persistent
RC. Of the 204 patients with follow-up data, 141 had
been treated with grass pollen vaccine only, 21 with
HDM only and 42 with grass pollen and HDM.
Nine (4.9%) of the grass pollen immunotherapy treated
patients started SCIT after the grass pollen season 2005
and were followed up after the 2006 season. The main
part of the grass pollen immunotherapy treated patients,
133 (72.7%) started SCIT after the 2006 pollen season
(cumulated pollen count during peak season: 1245
grains/m3 – ranked as a mild season) and were followed
up after the 2007 season (cumulated pollen count during
peak season: 1922 grains/m3 – ranked as a severe sea-
son) and the remaining 41 (22.4%) patients started im-
munotherapy treatment after the 2005 season
(cumulated pollen count during peak season: 1460
grains/m3 – ranked as a medium season) and were
followed up after the 2007 season (see Figure 1).
Outcomes
Among the 204 patients with available baseline and
follow-up data 11 patients had remission of their
RC, 30 had remission of their asthma and 3 patientshad remission of RC + asthma. Diagnostic criteria for
RC were no longer met in 8 patients at follow up.
Table 2 shows the diagnoses and classification of
rhino-conjunctivitis according to ARIA and asthma
according to the GINA guidelines by treatment
modality at baseline and at follow-up with an ITT
approach. At follow up, significantly fewer were
diagnosed with RC and asthma and the severity of
the diseases was diminished significantly (for RC p <
0.013, for asthma p < 0.001). The patients experi-
enced on average 44 fewer days with inconvenience
a year (p < 0.001) and 2.5 fewer sick days a year at
follow-up (p < 0.001). The HRQoL measures (RQLQ,
15D and EQ-5D) on days with allergen exposure
were all significantly improved (p < 0.001).
An estimate (based on 15D scores) of the QALY´s
gained per SCIT patient per year would be equivalent
to (0.03*145/365) + (0.98-0.83)* 44/365 = 0.03 QALYs
gained (where 0.98 and 0.83 are the 15D base-line
scores on a day without allergy and with allergy, 44
(189–145) is the number of days with allergy avoided
by SCIT, 0.03 (0.86-0.83) is the gain in HRQoL on a
day with allergy after SCIT and 145 are the number
of days with allergy after SCIT) see Table 2. Using
EQ-5D scores the annual QALY gain would be 0.06.
Table 3 presents three logistic regression models
with positive change in allergic RC diagnosis from
baseline to follow-up as dependent variable (= 1 loss
of diagnosis, which means cure); = 0 if no change of
diagnosis). The three models include each the rele-
vant HRQoL baseline measures RQLQ, EQ-5D and
15D, respectively, as independent variable along with
gender, age at inclusion, BMI, treatment modality
and clinic setting (public hospital = 0 or private
Table 2 Diagnoses and classification of rhino-conjunctivitis (RC) and asthma by treatment modality at baseline (B) and at follow-up (F) with an intension to
treat approach N = 248
Grass pollen only N = 169 House dust mites (HDM) only N = 25 Grass and HDM mites N = 54 Full sample N = 248
B F B F B F B F P-value
RC diagnosis, ± classification
RC diagnosis 169 166 25 23 54 48 248 237
No RC diagnosis 0 3 0 2 0 6 0 11 0,013 a
Intermittent RC 7 57 4 8 4 18 15 83
Persistent RC 162 109 21 15 50 30 233 154
Asthma diagnosis
Asthma diagnosis 81 70 12 8 28 24 121 102 < 0.001a
No asthma diagnosis 88 99 13 17 26 30 127 146
Intermittent 29 27 6 3 7 8 42 38
Mild Persistent 21 22 1 1 6 3 28 26
Moderate Persistent 28 18 4 3 11 12 43 33
Severe Persistent 3 3 1 1 4 1 8 5
Days with inconvenience last year mean (SD) 160.2 (105.1) 119.6 (118.5) 270.9 (102.8) 191.1 (137.6) 247.2 (134.0) 185.3 (142.8) 189.3 (119.9) 141.1 (123.4) < 0.001b


















RQLQ* 3.12 (0.68) 2.01 (0.78) 3.21 (0.66) 2.34 (0.76) 2.61 (0.79) 1.83 (0,85) 3.02 (0.74) 2.00 (0.80) < 0.001b
EQ-5D-score on days with no allergen exposure 0.98(0.06) 0.98 (0.07) 0.93 (0.13) 0.97 (0.08) 0.98 (0.05) 0.99 (0.04) 0.98 (0.07) 0.98 (0.07) 0.975
EQ-5D-score on days with allergen exposure 0.70 (0.18) 0.78 (0.15) 0.60 (0.30) 0.67 (0.27) 0.72 (0.18) 0.80 (0.15) 0.70 (0.20) 0.77 (0.17) < 0.001b
15D-score on days with no allergen exposure 0.98 (0.03) 0.98 (0.04) 0.97 (0.05) 0.97 (0.05) 0.98 (0.03) 0.99 (0.02) 0.98 (0.03) 0.98 (0.04) 0.180
15D-score on days with allergen exposure 0.83 (0.08) 0.86 (0.08) 0.79 (0.09) 0.81 (0.11) 0.83 (0.08) 0.88 (0.07) 0.83 (0.08) 0.86 (0.08) < 0.001b



















Table 3 Three models of predicting loss of the diagnoses of rhino-conjunctivitis (RC) (=1) at follow-up
Model one With RQLQ** in the
model
Model two With 15D-score in
the model
Model three With EQ-5D-score in
the model
Coefficient Std. Err P-value Coefficient Std. Err P-value Coefficient Std. Err P-value
Gender –male −0.900 0.754 0.232 −0.733 0.725 0.312 −0.696 0.722 0.335
Age at inclusion 0.069 0.029 0.018* 0.067 0.029 0.020* 0.070 0.029 0.018*
Body mass index −0.126 0.093 0.175 −0.123 0.100 0.218 −0.122 0.102 0.233
Vaccination modality House dust mites only 1.432 0.992 0.149 1.421 0.988 0.150 1.464 0.981 0.136
Grass pollen and house dust mites 1.367 0.808 0.091 1.697 0.762 0.026* 1.638 0.766 0.032*
HRQoL^^-scores at baseline −0.683 0.500 0.172 2.989 4.469 0.504 1.905 2.186 0.383
Vaccination place – private clinic 1.033 1.193 0.387 0.890 1.144 0.437 0.940 1.147 0.412
Constant −1.842 2.750 0.503 −6.343 3.941 0.108 −5.352 2.675 0.045
Number of observations 245 244 241
LR chi2 17.76 16.21 16.96
Prob > chi2 0.0131 0.0232 0.0177
Pseudo R2 0.1979 0.1808 0.1897
*p < 0.
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ment of allergic RC was positively associated with
increasing age (the RQLQ p = 0.018; the 15D p =
0.020; the EQ-5D p = 0.018), and treatment with two
allergens, i.e. grass pollen and HDM (the RQLQ p =
0.091; the 15D p = 0.026; the EQ-5D p = 0.032). Base-
line HRQoL-scores, gender, BMI and treatment
framework were not associated with the likelihood of
a loss of the RC diagnosis and irrespective of HRQL
instrument used.Discussion
According to this study, it seems that patients treated
with SCIT for allergic RC ± asthma experience reduced
disease severity, decreased days with allergy symptoms,
increased disease specific and generic HRQoL and de-
creased number of sick days, which are all highly rele-
vant patient related outcomes and of general importance
to the public health issues of allergic diseases.
The results indicate that SCIT provides improvements
in general quality of life. A conservative estimate (based
on 15D scores) of the QALY´s gained by SCIT was
equivalent to 0.03 QALYs gained per SCIT treated pa-
tient per year. Using EQ-5D scores the annual QALY
gain would be 0.06. Patients treated for both HDM and
grass pollen allergy achieved the greatest HRQoL-gains
measured on the two generic instruments.
Different HRQol instruments produced different mea-
sures and results. In this study three different but very
relevant instruments were applied to elucidate the HRQoL
scores. As observed in other studies, the ED-5D detected
a greater difference in HRQol-score as compared to the
15D instrument [19,20,28,29].The strength of applying generic instruments for the
assessment of HRQoL is that the total scores represent
a weighted average across dimensions, with the relative
weighting being based on the publics’ preferences.
Such evaluations represent a useful tool for decision
makers and may represent a valuable contribution to
the optimising of resource allocation across different
patient groups [30].
An ITT approach was applied, where the self-reported
baseline HRQoL-scores, number of sick days and days of
inconvenience were assumed unchanged at follow-up for
the 44 patients for whom follow-up data was not avail-
able. The reported SCIT effect is likely to be a conserva-
tive estimate, as some of the 44 study drop-outs did
complete the up-dosing phase and thereby have achieved
much of the gain by SCIT [31].
Patients filled in the questionnaires as they recalled a
typical day with allergen exposure and a typical day
without allergen exposure, which may have produced
some degree of recall bias. Although the exact correl-
ation between grass pollen exposure and AR and/or
asthma severity is unknown, the burden of AR and
asthma could be influenced by the GPS [26].
In this study the grass pollen allergic part of the in-
cluded patients constituted the main part of patients.
Since the main part of the patients treated with grass
pollen vaccine (72.7%) started SCIT after the 2006 pollen
season, which was a relatively mild season it is unlikely
that the effect size is exaggerated by the GPS or regres-
sion toward the mean.
Most of the patients in this study had their follow-up
evaluation after the 2007 pollen season, and this pollen
season was clearly higher in grass pollen count (ranked
as a severe season) compared to the two previous
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ment. The clinical improvements observed in this study
therefore represent conservative estimates and any bias,
e.g. regression to the mean, is likely to reflect an under-
estimation of the effect of SCIT.
The effectiveness of SCIT in the treatment of al-
lergic RC was positively associated with treatment
with two allergens, dual grass pollen-HDM. This is
because the period of the perennial symptoms in
those with HDM allergy in addition to a seasonal al-
lergy achieves a much longer time with improved
HRQoL compared to monosensitized persons, which
translate into a higher QALY.
One weakness of the study was the missing control
group and a possible placebo effect. It is however diffi-
cult in a real life setting to have a matched group for
correct comparison and this study report the findings
before and after the intervention. The gains in RQLQ
scores due to SCIT were in line with other studies
[6,32,33]. Earlier studies have typically focused on medi-
cine scores, symptom scores and sick days [32]. Because
of the inclusion of various outcome measures, based on
objective observations by allergy specialists as well as pa-
tients’ subjective experiences, this study provides evi-
dence of the positive effect of SCIT.
Women were more inclined to drop out of the study,
and there was also a tendency for those with lower levels
of education to drop out. The absolute difference in
numbers (see Table 1) was small suggesting that the im-
pact on results is limited. From an earlier study it was
found that allergic patients with a university degree as
well as younger patients were more likely to commence
a SCIT treatment [19,31] suggesting that motivations in
this sub-groups are higher.
An important effect of SCIT was a reduction in sick
days from work averaging 2.5 days and a reduction of 44
days of inconvenience per annum in the mixed grass
pollen and/or HDM allergic cohort. This effect is likely
to decrease the burden of disease significantly for pa-
tients, employers and for society. A conservative esti-
mate on gained sick days by excluding an outlier having
220 days of sick leave at baseline, still shows a significant
and important gain of average 1.6 days annual sick days
per SCIT treated patient and is in agreement with an
earlier study in Denmark from 2005, where the gain in
avoided sick days was found to be 2.1 days per year [31].
It is, however, important to stress that in this study only
absenteeism was included and no presenteeism was in-
corporated in the analyses, which makes the estimate
conservative since the productivity losses caused by be-
ing at work but producing less were not included. Pres-
enteeism is the situation where a person will attend
work while sick, which may be a disadvantage to the
health and work performance. Other studies have shownpresenteeism to constitute the greater part of produc-
tivity loss for the society [10].
Conclusions
This study shows that treatment with SCIT of allergic
patients suffering from RC and/or asthma is followed by
a marked improvement in all primary outcomes: diag-
nosis severity is reduced, HRQoL-scores, number of sick
days and days with inconvenience per year due to al-
lergy. All these outcome measures were captured in the
QALY measure, which estimated a QALY gain in the
order of 0.03-0.06 QALY´s.
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